LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler Sells 1,701 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 1,701 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.04, for a total transaction of $11,975.04. Following the completion of the transaction, the director owned 1,318,133 shares of the company’s stock, valued at $9,279,656.32. This trade represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Robert Bessler also recently made the following trade(s):

• On Friday, December 19th, Robert Bessler sold 119,942 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.04, for a total transaction of $844,391.68.
• On Thursday, December 18th, Robert Bessler sold 6,442 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $45,094.00.
• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $86,597.00.
• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total value of $558,206.30.

LifeStance Health Group Trading Up 0.1%

LFST opened at $7.06 on Wednesday. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $8.30. The stock has a market cap of $2.75 billion, a PE ratio of -235.33 and a beta of 1.13. The business has a 50 day moving average of $6.07 and a 200-day moving average of $5.38.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. The business had revenue of $363.81 million during the quarter, compared to analyst estimates of $355.06 million. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The company’s revenue for the quarter was up 16.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.02) earnings per share. Equities research analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. bought a new position in LifeStance Health Group during the first quarter valued at approximately $7,932,000. Squarepoint Ops LLC raised its holdings in shares of LifeStance Health Group by 259.1% during the 2nd quarter. Squarepoint Ops LLC now owns 1,360,054 shares of the company’s stock worth $7,031,000 after acquiring an additional 981,349 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of LifeStance Health Group by 43.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 230,000 shares of the company’s stock valued at $1,532,000 after acquiring an additional 70,000 shares during the last quarter. AXQ Capital LP purchased a new position in shares of LifeStance Health Group in the second quarter valued at $343,000. Finally, TD Asset Management Inc purchased a new position in shares of LifeStance Health Group in the second quarter valued at $780,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LFST has been the subject of a number of analyst reports. BMO Capital Markets assumed coverage on LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 price objective for the company. BTIG Research increased their target price on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday. UBS Group upped their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Barclays assumed coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.83.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.